Veracyte Stock Today
| VCYT Stock | USD 42.89 0.05 0.12% |
Performance14 of 100
| Odds Of DistressLess than 35
|
Veracyte is selling for under 42.89 as of the 28th of November 2024; that is 0.12 percent increase since the beginning of the trading day. The stock's last reported lowest price was 42.35. Veracyte has about a 35 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. Equity ratings for Veracyte are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of October 2013 | Category Healthcare | Classification Health Care |
The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis Prosigna Breast Cancer Assay for breast cancer diagnosis Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis and Immunoscore Colon Cancer test for colon cancer diagnosis. The company has 77.5 M outstanding shares of which 3.1 M shares are at this time shorted by private and institutional investors with about 4.66 trading days to cover. More on Veracyte
Moving together with Veracyte Stock
| 0.83 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
Moving against Veracyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Veracyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Bonnie Anderson | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Healthcare (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVeracyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Veracyte's financial leverage. It provides some insight into what part of Veracyte's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Veracyte (VCYT) is traded on NASDAQ Exchange in USA. It is located in 6000 Shoreline Court, South San Francisco, CA, United States, 94080 and employs 815 people. Veracyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.32 B. Veracyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 77.5 M outstanding shares of which 3.1 M shares are at this time shorted by private and institutional investors with about 4.66 trading days to cover.
Veracyte currently holds about 170.11 M in cash with 44.22 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.37.
Check Veracyte Probability Of Bankruptcy
Ownership AllocationThe majority of Veracyte outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Veracyte to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Veracyte. Please pay attention to any change in the institutional holdings of Veracyte as this could imply that something significant has changed or is about to change at the company.
Check Veracyte Ownership Details
Veracyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.8 M | |
| Bank Of America Corp | 2024-06-30 | 1.8 M | |
| Gw&k Investment Management, Llc | 2024-09-30 | 1.4 M | |
| Bamco Inc | 2024-09-30 | 1.1 M | |
| Goldman Sachs Group Inc | 2024-06-30 | 1.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 950.8 K | |
| Northern Trust Corp | 2024-09-30 | 948.4 K | |
| Fisher Asset Management, Llc | 2024-09-30 | 877.8 K | |
| William Blair Investment Management, Llc | 2024-09-30 | 811.8 K | |
| Blackrock Inc | 2024-06-30 | 7.8 M | |
| Vanguard Group Inc | 2024-09-30 | 7.7 M |
Veracyte Historical Income Statement
Veracyte Stock Against Markets
Veracyte Corporate Management
| Robert Brainin | Executive Officer | Profile | |
| John Leite | Chief Business | Profile | |
| Annie McGuire | Sr Counsel | Profile | |
| Tracy Morris | VP Communications | Profile |
Additional Tools for Veracyte Stock Analysis
When running Veracyte's price analysis, check to measure Veracyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Veracyte is operating at the current time. Most of Veracyte's value examination focuses on studying past and present price action to predict the probability of Veracyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Veracyte's price. Additionally, you may evaluate how the addition of Veracyte to your portfolios can decrease your overall portfolio volatility.